Pharsight

Xadago patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8278485 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Jun, 2027

(3 years from now)

US8076515 MDD US Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283380 MDD US Methods for treatment of parkinson's disease
Mar, 2031

(6 years from now)

Xadago is owned by Mdd Us.

Xadago contains Safinamide Mesylate.

Xadago has a total of 3 drug patents out of which 0 drug patents have expired.

Xadago was authorised for market use on 21 March, 2017.

Xadago is available in tablet;oral dosage forms.

Xadago can be used as adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.

Drug patent challenges can be filed against Xadago from 21 March, 2021.

The generics of Xadago are possible to be released after 21 March, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 21, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using SAFINAMIDE MESYLATE ingredient

NCE-1 date: 21 March, 2021

Market Authorisation Date: 21 March, 2017

Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes

Dosage: TABLET;ORAL

More Information on Dosage

XADAGO family patents

Family Patents